new appointments

APPOINTMENT OF SENIOR CLINICAL, REGULATORY AND BUSINESS
DEVELOPMENT TEAM
Sydney, 2 November 2007: Medical Therapies Limited (ASX: MTY) announced today
the appointment of a senior team to support the Company’s planned acquisition
and product development program.
Dr Terrence Chew and Mr Patrick Mallon will join Medical Therapies in their respective
consulting roles in Clinical and Regulatory Affairs and Business and Commercial
Development.
Based in the USA, Dr Chew and Mr Mallon will be implementing the Company’s
global clinical, regulatory and drug registration strategy.
Dr Terrence Chew is a senior clinical and drug registration expert. His previous roles
include Medical Director (Johnson & Johnson), Medical Research Director (Agouron,
now Pfizer) and VP Clinical and Regulatory Affairs (Peregrine Pharmaceuticals).
Dr Chew, a medical practitioner and oncology specialist, has USA Regulatory Affairs
Certification and is a Member of the American College of Physicians, the American
Society of Clinical Oncology, the American Society of Oncology and the Regulatory
Affairs Professional Society in the USA.
Dr Chew will provide drug development expertise to Medical Therapies including
assisting with the selection of in-licensed compounds, evaluation of clinical drug
candidates and development and implementation of clinical trial and regulatory
strategy.
Mr Patrick Mallon is a senior business and commercialisation strategist in the medical
research industry. He has a strong track record in taking products to market in the
therapeutic, medical device and diagnostic areas in both major pharmaceutical
and in biotechnology companies. As Group Director at Roche, Worldwide Business
Development and Planning, Mr Mallon directed the strategic and commercial
development of a number of therapeutic areas including oncology.
Mr Mallon will provide assistance with strategic planning, product profiling, market
assessment, financial and economic analysis, license origination and negotiation,
along with product launch support to Medical Therapies.
Medical Therapies Managing Director and CEO Maria Halasz commented:
“We are delighted to announce the appointment of Dr Chew and Mr Mallon. They
bring to Medical Therapies a strong track record in pharmaceutical development,
drug registration and commercialisation gained with large pharmaceutical and
biotechnology companies in the USA and Europe.”